The benchmarking and application of tag-degraders in vivo to validate therapeutic targets
Journal Title
Nature Communications
Publication Type
Online publication before print
Abstract
Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degradation of any protein of interest via a degron-tag. This drug-based, reversible, and dose-dependent method of protein removal can mimic degrader-based drug treatments and assess the implications of target protein depletion in vivo. However, each degrader has a distinct pharmacokinetic profile that will influence its effectiveness across tissues. To create a resource to enable the most appropriate choice of tag-degrader, we benchmark the dTAG, HaloPROTAC, and NanoTAC systems in vivo by employing a transgenic mouse expressing a reporter protein targetable by these tag-degraders. Through various treatment regimes, we characterise each degrader profile across a panel of 20 tissues and organs, highlighting the superior degradation by dTAG molecules, and identify differences between degradation in whole tissues versus single cell populations. Using an FKBP(F36V) knock-in mouse expressing 65K-FKBP(F36V), we reveal target specific degradation kinetics, and a critical requirement for 65K in mice. Together, this resource will assist researchers in choosing the right degrader and tag for their own applications.
Department(s)
Haematology
Open Access at Publisher's Site
https://doi.org/10.1038/s41467-026-73681-1
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-06-04 11:59:38
Last Modified: 2026-06-04 12:00:13
An error has occurred. This application may no longer respond until reloaded. Reload 🗙